Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxium for diabetic retinopathy
IRCT20220817055729N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in diabetic retinopathy (DR) comparing Doxium with Placebo (2 arms). Primary endpoints: Macular thickness and Visual acuity. Started Sep 2022; status: completed.
02
Drugs
calcium dobesilate
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on IRCT20220817055729N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220817055729N1.